RCKT

RCKT

Rocket Pharmaceuticals Inc. Common Stock

$3.070+0.000 (0.000%)

Цена в режиме реального времени

График цен

Loading Chart...

Ключевые показатели

Рыночные показатели
Фундаментальные показатели компании
Статистические данные торговли

Рыночные показатели

Открытие

$3.070

Максимум

$3.070

Минимум

$3.070

Объем

3.11M

Фундаментальные показатели компании

Статистические данные торговли

Связанные новости

Analyst Upgrades

Canaccord Genuity Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $11

Canaccord Genuity analyst Whitney Ijem maintains Rocket Pharmaceuticals with a Buy and lowers the price target from $34 to $11.

Просмотреть больше
Canaccord Genuity Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $11
Analyst Upgrades

Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty

Rocket Pharmaceuticals faces trial delays, multiple downgrades, and reduced success expectations following RP-A501 safety concerns.

Просмотреть больше
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty
Analyst Upgrades

Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty

Rocket Pharmaceuticals faces trial delays, multiple downgrades, and reduced success expectations following RP-A501 safety concerns.

Просмотреть больше
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty
Analyst Upgrades

B of A Securities Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $9

B of A Securities analyst Greg Harrison maintains Rocket Pharmaceuticals with a Buy and lowers the price target from $32 to $9.

Просмотреть больше
B of A Securities Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $9
Analyst Upgrades

BMO Capital Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $8

BMO Capital analyst Kostas Biliouris maintains Rocket Pharmaceuticals with a Outperform and lowers the price target from $30 to $8.

Просмотреть больше
BMO Capital Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $8
Analyst Upgrades

Scotiabank Maintains Sector Outperform on Rocket Pharmaceuticals, Lowers Price Target to $19

Scotiabank analyst Greg Harrison maintains Rocket Pharmaceuticals with a Sector Outperform and lowers the price target from $51 to $19.

Analyst Upgrades

Leerink Partners Downgrades Rocket Pharmaceuticals to Market Perform, Lowers Price Target to $8

Leerink Partners analyst Mani Foroohar downgrades Rocket Pharmaceuticals from Outperform to Market Perform and lowers the price target from $37 to $8.

Оставаться в курсе

Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.